La Jolla Pharmaceutical (NASDAQ:LJPC) perks up 4% premarket on light volume in reaction to its announcement that
it is supplying Giapreza (angiotensin II) for COVID-19 patients with
septic shock under an emergency medical program at a hospital in
Belgium.
The FDA approved Giapreza in December 2017 for adults with septic shock or other distributive shock.
https://seekingalpha.com/news/3560113-la-jolla-pharma-up-4-on-giapreza-for-covidminus-19-septic-shock
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.